Momenta Pharmaceuticals, Inc.

Cuihua Liu

Xiao-Jin Xu

Shiming Dong

Zachary Shriver

Carlos J Bosques

Jonathan C Lansing

Yanjie Jiang

Jennifer Murphy

Ganesh Venkataraman

Nur Sibel Gunay

Ishan Capila

Nathaniel J Washburn

Hetal Sarvaiya

Mallikarjun Sundaram

Daniela Beccati

Corinne Bauer

Yiwei Qi

Yiming Yao

Pat Oliver-Shaffer

Zainab Sirajbhai Mamuwala

Ian David Fier

Sibel Nur Gunay

Ying Li

Guy Dellorusso

Jennifer Lynn Murphy

Methods of producing recombinant therapeutic fusion proteins described herein can include culturing Chinese hamster ovary (CHO) cells under conditions suitable for expression of a recombinant therapeutic fusion protein including one or more glycans, where the CHO cells have not been genetically engineered to produce terminal alpha-galactosyl residues on glycans; treating the one or more glycans of the recombinant glycoprotein with one or more exoglycosidases; measuring glycans containing terminal galactose-alpha-1-3-galactose residues on the fusion protein by nuclear magnetic resonance (NMR); and producing a recombinant therapeutic fusion protein in the CHO cells if a target level of terminal galactose-alpha-1-3-galactose residues is measured.

Galactose-alpha-1, 3-galactose-containing n-glycans in glycoprotein products derived from CHO cells

Among other things, the present disclosure provides methods for enriching, identifying, and/or quantifying unusually modified glycans (e.g., phosphorylated glycans, sulfated glycans, and/or multi-acetylated glycans). In many embodiments, methods comprise providing a glycan preparation from which sialic acids have been released; subjecting the sialidase-treated glycan preparation to a separation technique that separates glycans based on charge-to-mass ratio; and quantifying the charged products using at least one quantification standard.

Methods related to modified glycans

Methods of analyzing glatiramer acetate (GA) or a polymeric precursor thereof are provided. The methods can include determining a level of one or more diethylamide-modified amino acids in a sample comprising GA or a polymeric precursor thereof, and selecting at least a portion of the sample based on the assessment of the one or more diethylamide-modified amino acids in the sample.

Evaluation of copolymer diethylamide

The present disclosure provides methods for analyzing structure and/or composition of glycoproteins and glycans of glycoproteins. Such methods can include subjecting a glycoprotein preparation to a condition that removes at least one O-linked glycan from the glycoprotein. Such methods can include subjecting a glycoprotein preparation to a condition that releases an N-glycan from the glycoprotein, e.g., prior to subjecting the glycoprotein to a condition that releases an O-glycan from the glycoprotein.

[object Object]

Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.

Low molecular weight heparin composition and uses thereof

The present invention provides methods of evaluating CHO cells.

Gal &#x3b1;1-3gal-containing N-glycans in glycoprotein products derived from CHO cells

Methods for analyzing mixtures of polysaccharides, for example heparin or a LMWH, using reduce end labeling are described. In general, the mixture of polysaccharides includes polysaccharides having a desired structural moiety. In some instances, one or more polysaccharides in the mixture are chemically modified prior to analysis.

Methods of evaluating mixtures of polysaccharides

Growing community of inventors

Belmont, MA, United States of America

Cuihua Liu